Omnicell (OMCL) Stock Overview
Provides healthcare technology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OMCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.10 |
| 52 Week High | US$55.00 |
| 52 Week Low | US$22.66 |
| Beta | 0.77 |
| 1 Month Change | -15.26% |
| 3 Month Change | 6.86% |
| 1 Year Change | 8.93% |
| 3 Year Change | -24.89% |
| 5 Year Change | -66.75% |
| Change since IPO | 332.18% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
Feb 12
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Nov 13Omnicell Q2 Earnings: Market Ignoring The Segments
Jul 31Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
Jul 16Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 28
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
May 14US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
May 09Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Apr 07Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Mar 20Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Feb 14Omnicell Q4 Earnings: Ignore The Short-Term Noise
Feb 12Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 28Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
Nov 27Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Nov 02Omnicell Q3 Earnings: Look At The Growth Segment
Nov 01Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Oct 31Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%
Aug 02Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?
Jul 11Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price
Jun 16Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt
May 25An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued
Mar 28Shareholder Returns
| OMCL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.9% | 1.1% | -0.6% |
| 1Y | 8.9% | -7.3% | 15.5% |
Return vs Industry: OMCL exceeded the US Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: OMCL underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OMCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OMCL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,600 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
Omnicell, Inc. Fundamentals Summary
| OMCL fundamental statistics | |
|---|---|
| Market cap | US$1.87b |
| Earnings (TTM) | US$2.05m |
| Revenue (TTM) | US$1.18b |
Is OMCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMCL income statement (TTM) | |
|---|---|
| Revenue | US$1.18b |
| Cost of Revenue | US$676.80m |
| Gross Profit | US$508.04m |
| Other Expenses | US$505.99m |
| Earnings | US$2.05m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.045 |
| Gross Margin | 42.88% |
| Net Profit Margin | 0.17% |
| Debt/Equity Ratio | 13.6% |
How did OMCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 21:46 |
| End of Day Share Price | 2026/02/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |